VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2019 | Venetoclax with azacitidine in HR-MDS

Andrew Wei, MBBS, PhD, Alfred Hospital and Monash University, Melbourne, Australia, covers the phase 1b trial (NCT02942290) of venetoclax in combination with azacitidine in treatment-naïve patients with higher-risk myelodysplastic syndrome (MDS). This revealed a tolerable safety profile and promising efficacy. This interview was recorded at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter